JP2017537899A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537899A5
JP2017537899A5 JP2017526088A JP2017526088A JP2017537899A5 JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5 JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
dissolution
formula
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537899A (ja
JP6829684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061194 external-priority patent/WO2016081523A1/en
Publication of JP2017537899A publication Critical patent/JP2017537899A/ja
Publication of JP2017537899A5 publication Critical patent/JP2017537899A5/ja
Application granted granted Critical
Publication of JP6829684B2 publication Critical patent/JP6829684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526088A 2014-11-17 2015-11-17 癌を処置する方法 Active JP6829684B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US62/080,985 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US62/166,572 2015-05-26
US201562251903P 2015-11-06 2015-11-06
US62/251,903 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021008382A Division JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2017537899A JP2017537899A (ja) 2017-12-21
JP2017537899A5 true JP2017537899A5 (enExample) 2018-12-27
JP6829684B2 JP6829684B2 (ja) 2021-02-10

Family

ID=56014476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017526088A Active JP6829684B2 (ja) 2014-11-17 2015-11-17 癌を処置する方法
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Country Status (20)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP3220916B1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (3) KR102964530B1 (enExample)
CN (2) CN107249591B (enExample)
AU (4) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
EA038337B1 (ru) 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
KR102964530B1 (ko) 2014-11-17 2026-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
CA3249707A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
WO2026117542A1 (en) 2024-11-26 2026-06-04 Arvinas Operations, Inc. Combination therapy for the targeted degradation of bcl6

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
WO2008121476A1 (en) * 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2663283B1 (en) * 2011-01-14 2017-05-10 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA3177515A1 (en) 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
EP2836216B1 (en) * 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
KR20190105669A (ko) * 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
PE20161273A1 (es) * 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
EA038337B1 (ru) * 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
KR102964530B1 (ko) 2014-11-17 2026-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
EA201890009A1 (ru) * 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
US11147819B2 (en) * 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer

Similar Documents

Publication Publication Date Title
ES2957912T3 (es) Composiciones farmacéuticas que comprenden nilotinib
KR102338802B1 (ko) 암을 치료하기 위한 방법
JP2023036772A (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
US11065240B2 (en) Drug combinations to treat multiple myeloma
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
JP2021530554A5 (enExample)
JP2013536243A5 (enExample)
RU2712187C2 (ru) Фармацевтические композиции и их применение
ES2792574T3 (es) Formulación de Ceritinib
JP2015534985A5 (enExample)
KR20200121302A (ko) 간세포성 암종의 치료를 위한 조합 요법
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
WO2011081118A1 (ja) 経口投与用医薬組成物
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
HK1225281B (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
WO2015063669A1 (en) Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof